A new, and unique, stem cell therapy for MS patients! :)

It is always great news to hear about the use of stem cells as therapies for MS. There seems to be great hope for the future with the use of these and we can only be positive about what is coming :)

I look very much forward to hearing the results of this research and hope we will all be able to benefit from it, soon :)


Enjoy the read: http://guardianlv.com/2013/08/unique-stem-cell-therapy-for-ms-patients/


Stay well!



Promising trials – for MS as well – w. ADULT stem cells use! :)

More good news ahead this sunny day.. :

Using adult stem cells (not embryonic) the researchers have shown both sensation and motor improvements in patients with spinal cord injuries.

Read the whole article here: http://www.mycentraljersey.com/article/20130602/NJNEWS/306020011?odyssey=mod%7Cmostcom


Warm regards,


New MS therapies expected in 2012

Hi all,

I have just come across this interesting video where Dr. Ben Turner quickly highlights the key new MS therapies we can expect in 2012.

Among these you will hear a bit about Fingolimod (Gylenia), Teriflunomide (Aubagio), BG12 (Biogen’s nr. 12 drug) and Alemtuzumab (Lemtrada). He briefly introduces the drugs and gives a short explanation of the known benefits, supported by graphs.

To view the video click here: http://shift.ms/magazine/2012/02/new-therapies-what’s-around-the-corner-in-2012/

Never give up! =)

More genes than previously thought linked to MS!

A new discovery that came from a research aimed at finding out what role genes play in MS has now identified an additional 29 genes adding to a total of 57 genetic clues for MS.

However, it is still emphasized that genes play only a part in MS risk. Other factors, such as vitamin D levels and viral exposure are also believed to play a role. We know that the further somebody is from the equator, the higher his/her risk is (vitamin D from sunlight may be a factor).

The authors explained that T-cells and interleukins appear to play a major role in the development of MS. (…)

Co-author, Alastair Compston, from Cambridge University, said:

“We have implicated genes that are highly relevant to the actions of those drugs. It is now clear that multiple sclerosis is primarily an immunological disease. This is the way to nail this disease and get on top of it.”

(Source: Medical News Today August 10th 2011.)

Ocrelizumab – reduces MS disease activity

As taken from the Medical News Today (Oct. 20.2010) website:

Ocrelizumab is an investigational humanized monoclonal antibody designed to selectively target CD20-positive B-cells, which are believed to play a critical role in multiple sclerosis (MS). It then interacts with the body’s immune system to eliminate CD20-positive B-cells.

Simply put, Ocrelizumab has demonstrated, through trials (they refer to phase II in particular), that there is a significant reduction in disease activity in patients with MS…as measured by brain lesions and relapse rate.

In fact, the reductions were impressive: the total reductions in the number of brain lesions detected by MRI scanning was 96% for 2000mg Ocrelizumab and 89% for 600mg Ocrelizumab (compared to placebo). Disease activity was also reduced significantly…

For more info on Ocrelizumab please visit the Medical News Today link (you can find under “links”).

Disease activity was also measured by reduction in annualized relapse rate (ARR), the rate of attacks or flare-ups per patient-year. At week 24, ARR was significantly lowered versus placebo with a reduction of 73% for ocrelizumab 2000mg and 80% for ocrelizumab 600mgii.


Fingolimod approved!

…and so just a follow up on my previoud posts…

Fingolimod (Gilenya) has finally been approved by the FDA. Gilenya (fingolimod) is a 0.5 mg (capsule) daily oral treatment for relapsing MS.

Novartis, stated that Gilenya is the first oral medication indicated for relapsing forms of multiple sclerosis (MS) in the United States – it reduces the frequency of MS flare-up, as well as helping slow down the build-up of some of the physical problems associated with MS.

Yeay! more oral drugs – we like! : )

Oral Laquinimod for MS!

I’d like to mention briefly Laquinimod here..

Laquinimod is an investigational, novel, once-daily oral immunomodulator. It was developed as a disease-modifying treatment for RRMS and is nearing end of trial phase. It is expected to be completed by Q3 next year!

Besides being tested for the treatment of RRMS, it is in development for Crohn’s disease and Lupus, and is being researched for other autoimmune diseases as well!

On September 21st, Medical News Today reported that, thus far, Laquinimod has demonstrated a sustained positive benefit-risk profile through the trials undertaken. Doctors are looking forward to confirming these in the final study phases next year.

We have one more oral drug for MS to look forward to!! : )

Previous Older Entries